SOUTH SAN FRANCISCO, Calif., Jan. 22, 2025 (GLOBE NEWSWIRE) — ALX Oncology Holdings, Inc. (ALX Oncology or the Firm), (Nasdaq: ALXO), a clinical-stage biotechnology firm advancing therapies that enhance the immune system to deal with most cancers and prolong sufferers’ lives, at present introduced that efficient January 21, 2025, the Compensation Committee of the Board of Administrators of ALX Oncology granted an inducement inventory choice to buy a complete of 600,000 shares of ALX Oncology’s frequent inventory to Harish Shantharam, the Firm’s Chief Monetary Officer, in reference to the graduation of his employment. Mr. Shantharam’s inducement inventory choice is topic to the phrases of the ALX Oncology Holdings Inc. 2025 Inducement Fairness Incentive Plan and associated types of agreements, and have been granted as inducements materials to Mr. Shantharam to enter into employment with ALX Oncology in accordance with Nasdaq Itemizing Rule 5635(c)(4).
The inducement inventory choice has an train value of $1.65 per share, which is the same as the closing value of a share of ALX Oncology frequent inventory on the grant date, and shall vest as follows: 25% of the shares topic to such inducement inventory choice shall vest on the one yr anniversary of January 21, 2025 and an extra one forty-eighth of the shares topic to such inducement inventory choice shall vest month-to-month thereafter, topic to the worker’s continued service.
About ALX Oncology
ALX Oncology (Nasdaq: ALXO) is a clinical-stage biotechnology firm advancing therapies that enhance the immune system to deal with most cancers and prolong sufferers’ lives. ALX Oncology’s lead therapeutic candidate, evorpacept, has demonstrated potential to function a cornerstone remedy upon which the way forward for immuno-oncology may be constructed. Evorpacept is at the moment being evaluated throughout a number of ongoing scientific trials in a variety of most cancers indications. Extra data is offered at www.alxoncology.com and on LinkedIn @ALX Oncology.
Firm Contact:
Allison Dillon, Chief Business Officer, ALX Oncology
ir@alxoncology.com
Media Contact:
Audra Friis, Sam Brown, Inc.
audrafriis@sambrown.com
(917) 519-9577
Supply: ALX Oncology
